Biotech

• The FDA has granted a new indication for the drug Tzield, expanding its use to patients who have already progressed to Stage 3 type 1 diabetes. • This latest approval aims to preserve residual beta cell function, building on previous expansions in April 2026 that extended the drug's use to children as young as one year old. • The decision was based on the PROTECT trial, which demonstrated a statistically significant effect on C-peptide, a surrogate endpoint used to predict clinical benefit.

• Anthropic announced the acquisition of Coefficient Bio, a U.S.-based AI startup specializing in biological modeling, on April 27, 2026. • The deal aims to integrate Coefficient's protein design AI tools with Anthropic's Claude models for advanced drug discovery applications. • This move positions Anthropic in the competitive AI-biotech space amid rising investments, potentially accelerating personalized medicine breakthroughs.

• Anthropic acquired Coefficient Bio, a startup founded eight months ago with fewer than 10 employees, for roughly $400 million in shares, despite it having no product or revenue. • The platform uses AI for pharmaceutical tasks like drug research planning and identifying new drug opportunities, positioning Anthropic's models for scientific discovery in life sciences. • This bet signals a strategic push into AI-driven biotech, potentially accelerating drug development amid growing competition in applied AI verticals.

Biotech firm Immutep Ltd. crashed more than 80% on March 13, 2026, becoming one of the biggest decliners amid a mixed US market session pressured by geopolitical fears. The plunge contrasted with gains in AI leaders like Intel (+1.7%), Tesla (steady at $395), and Nokia (+1.4%), highlighting sector rotation. This extreme volatility amplifies risks in biotech amid elevated VIX at 26.49 and weekly index losses. Investors may monitor clinical trial updates or funding news for rebound potential.